Pharmacological treatment for COVID-19 in latin american protocols: A narrative review of the effectiveness and safety

• Autor(a) principal: Saavedra, Pamela Alejandra Escalante
• Data de Publicação: 2020
• Outros Autores: Cañás, Martín, Barbado, Dulce María Calvo, Esparza, Liliana Barajas, Caffaratti, Mariana, Speranza, Noelia, Martínez, Carlos Fuentes, Guitiérrez, José Julián López
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: Vigilância Sanitária em Debate
• Texto Completo: https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1741
• topic: COVID-19; Clinical protocols; Medicaments; Evidence-Based Medicine; Latin America; COVID-19; Protocolos Clínicos; Medicamentos; Medicina Basada en Evidencia; Latinoamérica; COVID-19; PROTOCOLOS CLÍNICOS; MEDICAMENTOS; MEDICINA BASEADA EM EVIDÊNCIA

Introduction: The pandemic caused by SARS-CoV-2 has put the global scientific community in an accelerated pace of research for an effective treatment for COVID-19. Objective: To identify and evaluate drugs in Latin American protocols of pharmacological treatment for COVID-19. Method: The evidence and mega trial results available to date on the most frequent medications are analyzed. Results: The most common drugs in national protocols are hydroxychloroquine, lopinavir/ritonavir, and remdesivir. None of the drugs that collect the most data from clinical studies, with the except for dexamethasone in a small subgroup of patients, so far showed significant differences in mortality. Conclusions: The emerging situation of COVID-19 has determined hasty and controversial decision-making based on questionable and/or low-quality studies. This highlights the provisional nature of the information and the possibility of generating changes as more results become available. Advance medication authorization exposes a known problem. Although regulatory agility is required at this time, speed should not overlap with basic ethical standards and trust in evidence.